The Baxter Evolving Health Programme has been set up to work in consultation with NHS Trusts to find innovative solutions that meet with the QIPP agenda. We are committed to helping you find ways to do things differently, to improve quality for patient care and also to release savings.
We are driven by the NHS goal to improve outcomes for patients more efficiently. Our expertise across the entire patient pathway means we are uniquely placed to identify opportunities for service redesign, whether it is in effective and fully integrated long-term condition programmes, smarter ways of managing demand for acute care or managing procurement and business management services to improve both efficiencies and patient experience.
We want to work in true partnership with NHS clinicians and managers, developing tailored and practical solutions to problems specific to your Trust. Together we have a real opportunity to deliver on QIPP objectives with a win-win scenario for all, and most importantly the patient. Please contact your local Evolving Health consultant to see how we can help you.
"The QIPP initiative is identifying how efficiencies can be driven and services redesigned to achieve the twin aims of improved quality and efficiency."
Equity and Excellence: Liberating the NHS, Department of Health white paper, July 2010
"We need an entirely new relationship with industry based on partnership, not just transactions."
David Nicholson - Innovation, Health and Wealth, Accelerating Adoption and Diffiusion in the NHS, Department of Health, December 2011
Anaesthesia
Anaesthesia has played a major role in making surgical intervention a viable therapeutic option in healthcare.
There are two basic categories of anaesthesia: general anaesthesia, which renders the patient unconscious, and local or regional anaesthesia, which blocks sensation in a particular area of the body. Baxter is a leading manufacturer of products for general anaesthesia. These include anaesthetic gases, or inhaled anaesthetics, and anaesthesia-related critical care drugs.
Click here for further information.
BioSurgery
Blood Conservation
Perioperative blood management is a major challenge facing the NHS. The consequences are far reaching for patients and hospitals alike. BioSurgery are proud to offer a range of products to help surgeons meet this challenge head on.
Hernia Mesh Fixation
BioSurgery offer a fibrin sealant which provides the patient and surgeon with an alternative to mechanical mesh fixation.
Active Bone Regeneration
BioSurgery offer a range of synthetic bone graft substitutes aimed at improving the quality and increasing the speed at which bone formation occurs following spinal fusion.
Adhesion Prevention
Postoperative adhesions can be problematic for the patient and surgeon. Lysis of adhesions is often time-consuming and incurs costs. Baxter offers a range of site-specific and general adhesion reduction therapies for the surgeon to use.
Cerebrospinal Fluid Preservation
Preventing CSF leakage can be a major concern in both cranial and spinal surgery. The BioSurgery portfolio includes a dural sealant and dural replacement to meet this surgical challenge.
Aerostasis
Patients undergoing thoracic surgery can develop intraoperative air leaks which can have consequences. BioSurgery provides a synthetic surgical sealant to allow the surgeon to seal lung tissue.
Click here for further information.
Clinical Nutrition
At Baxter we understand that meeting your patients’ individual parenteral nutritional requirements is imperative. Therefore Baxter is committed to developing essential parenteral nutrition products and services for both hospital and community patients.
Click here for further information.
Critical Care
Baxter's critical care therapies includes albumin which is primarly used as plasma-volume replacement therapy for the treatment of hypovolemia.
Human albumin is an essential protein found in human plasma.
Albumin supplementation restores intravascular volume and maintains cardiac output and colloid osmotic pressure.
Click here for further information.
Haemophilia
Baxter is committed to actively listening to and working with the haemophilia community to proactively shape the future of haemophilia by focusing on personalised innovations and solutions.
Baxter's range of haemophilia therapies allows clinicians to choose the appropriate therapy based on individual patient needs.
Click here for further information.
Homecare
Our focus is to provide homecare which is responsive, professional and empathetic in meeting the needs of patients and the NHS. We have developed new ways of assisting patients in managing their treatments at home and have a proven track record of fulfilling promises made to Trusts.
Click here for further information.
Immunoglobulin
There are effective treatment options for most patients with primary immunodeficiency (PID), although the types of treatments differ based on the type of PI.
Click here for further information.
Infusion Systems/IV Tubing
The infusion systems portfolio provides healthcare professionals with a range of products for the administration of intravenous medications and solutions that promote appropriate and cost effective fluid delivery.
Click here for further information.
IV Solutions, Drug Delivery and Irrigation
Baxter is one of the world's leading manufacturers of commercially prepared IV solutions and ready-to-use premixed drugs in flexible IV containers. Baxter also has a range of irrigation solutions and sets to suit a wide range of applications.
Click here for further information.
Renal
Baxter develops, manufactures and markets a comprehensive selection of products and services used in the treatment of kidney disease.
Click here for further information.
Vaccines
Baxter's influenza vaccines are produced using the company's unique Vero-cell technology which the potential to significantly reduce production time compared to traditional vaccine production methods using embryonated hens' eggs.
Baxter also produces leading vaccines for prevention of meningitis C, a highly infectious disease characterised by rapid onset of life-threatening and debilitating symptoms, and tick-borne encephalitis, a potentially fatal disease common in Europe.
Click here for further information.
Through our Evolving Health Programme, Baxter is partnering with the NHS to deliver the current QIPP agenda. We are committed to helping you find ways to do things differently, to release savings while improving quality and patient experience.
- Service Redesign
- Patient Safety
- Financial Stability
- Patient Experience
- Risk Management
- Care Pathway
- Service Redesign
- Patient Safety
- Financial Stability
- Patient Experience
- Risk Management
- Care Pathway
